Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07018297 · ClinicalTrials.gov registry record · Phase 3
Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure
A Phase 3 study, sponsored by University of Texas Southwestern Medical Center.
- Not yet
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
NCT07018297 is a Phase 3 study that has not yet begun recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 250 participants.
The verdict
NCT07018297, a Phase 3 study, has not yet begun recruiting, sponsored by University of Texas Southwestern Medical Center.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
Study Summary
This will be a prospective, cluster-randomized, crossover, non-inferiority trial of 250 participants within 48 hours of an inpatient admission for heart failure or emergency department presentation for heart failure with plans for admission or observation/short-stay hospitalization comparing early discharge using subcutaneous furosemide to standard inpatient care. Individual practice groups will serve as "clusters" and the unit of randomization. Each participating cluster will implement either the early discharge strategy using the intervention or standard care for initial two-month blocks, followed by a crossover to the alternate strategy. The primary outcome is days alive and out of hospital at 30 days.
Interventions
- COMBINATION_PRODUCT Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2026-08 |
| Est. Completion | 2028-09-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07018297
The ClinicalTrials.gov registry entry for NCT07018297 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor is the first listed.
NCT07018297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07018297 about?
NCT07018297 is a clinical study titled "Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure". This will be a prospective, cluster-randomized, crossover, non-inferiority trial of 250 participants within 48 hours of an inpatient admission for heart failure or emergency department presentation for heart failure with plans for admission or observation/short-stay hospitalization comparing early d...
What is the current status of trial NCT07018297?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2026-08. Estimated completion is 2028-09-01.
What interventions are being tested in trial NCT07018297?
The interventions under investigation include: Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07018297?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.